UnitedHealth Group (NYSE:UNH) had its price target lowered by Barclays from $290.00 to $270.00 in a research note published on Wednesday morning, BenzingaRatingsTable reports. The firm currently has an overweight rating on the healthcare conglomerate’s stock.
A number of other brokerages also recently commented on UNH. ValuEngine downgraded UnitedHealth Group from a buy rating to a hold rating in a research report on Wednesday, February 27th. Credit Suisse Group reiterated a buy rating and set a $310.00 price objective on shares of UnitedHealth Group in a research report on Friday, February 8th. Oppenheimer increased their price objective on UnitedHealth Group from $300.00 to $305.00 and gave the company an outperform rating in a research report on Wednesday, January 16th. Zacks Investment Research downgraded UnitedHealth Group from a buy rating to a hold rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald reissued a buy rating and set a $310.00 target price on shares of UnitedHealth Group in a research note on Tuesday, January 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. UnitedHealth Group currently has an average rating of Buy and a consensus price target of $291.56.
Shares of NYSE:UNH opened at $221.75 on Wednesday. UnitedHealth Group has a one year low of $208.07 and a one year high of $287.94. The firm has a market cap of $212.78 billion, a PE ratio of 17.22, a P/E/G ratio of 1.18 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.73 and a quick ratio of 0.73.
UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings data on Tuesday, April 16th. The healthcare conglomerate reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.60 by $0.13. UnitedHealth Group had a return on equity of 24.38% and a net margin of 5.30%. The company had revenue of $60.30 billion during the quarter, compared to the consensus estimate of $59.72 billion. During the same quarter in the prior year, the firm earned $3.04 EPS. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. On average, equities research analysts expect that UnitedHealth Group will post 14.63 EPS for the current year.
In other news, Director William C. Ballard, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $266.61, for a total value of $1,333,050.00. Following the transaction, the director now directly owns 77,702 shares of the company’s stock, valued at $20,716,130.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gail R. Wilensky sold 2,930 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $253.39, for a total transaction of $742,432.70. Following the completion of the transaction, the director now directly owns 64,726 shares in the company, valued at $16,400,921.14. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,930 shares of company stock worth $4,587,133. Company insiders own 0.87% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Partners LLC increased its stake in shares of UnitedHealth Group by 6.5% in the fourth quarter. Advisor Partners LLC now owns 31,893 shares of the healthcare conglomerate’s stock worth $7,945,000 after acquiring an additional 1,949 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of UnitedHealth Group by 7.3% in the third quarter. TIAA CREF Investment Management LLC now owns 5,462,680 shares of the healthcare conglomerate’s stock worth $1,453,291,000 after acquiring an additional 370,179 shares during the last quarter. Financial Enhancement Group LLC increased its stake in shares of UnitedHealth Group by 2,579.3% in the third quarter. Financial Enhancement Group LLC now owns 1,554 shares of the healthcare conglomerate’s stock worth $413,000 after acquiring an additional 1,496 shares during the last quarter. Legacy Bridge LLC acquired a new position in UnitedHealth Group during the fourth quarter worth $824,000. Finally, LS Investment Advisors LLC increased its position in UnitedHealth Group by 38.9% during the fourth quarter. LS Investment Advisors LLC now owns 34,921 shares of the healthcare conglomerate’s stock worth $8,700,000 after buying an additional 9,784 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
See Also: Blue-Chip Stocks
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.